Chemotherapy of ovarian cancer directed by the human tumor stem cell assay

[1]  D. Alberts,et al.  Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[2]  D. V. Von Hoff,et al.  Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid. , 1981, Cancer treatment reports.

[3]  D. Alberts,et al.  IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY , 1980, The Lancet.

[4]  T. Miller,et al.  Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors. , 1980, Cancer treatment reports.

[5]  D. Alberts,et al.  In vitro drug assay: pharmacologic considerations. , 1980, Progress in clinical and biological research.

[6]  R. Makuch,et al.  cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. , 1979, Cancer treatment reports.

[7]  S. Salmon,et al.  Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. , 1979, Cancer research.

[8]  S. Vogl,et al.  The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). , 1979, Cancer treatment reports.

[9]  L. Einhorn,et al.  Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. , 1979, Cancer treatment reports.

[10]  R. Fisher,et al.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.

[11]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[12]  M. D’Incalci,et al.  Adriamycin in ovarian cancer patients resistant to cyclophosphamide. , 1978, European journal of cancer.

[13]  J. Trent,et al.  Direct cloning of human ovarian carcinoma cells in agar. , 1978, Cancer research.

[14]  R. Young,et al.  Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. , 1978, Cancer treatment reports.

[15]  D. Alberts,et al.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. , 1978, The New England journal of medicine.

[16]  M. Rabinovitz,et al.  Amino acid-conferred protection against melphalan--characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells. , 1978, Biochemical pharmacology.

[17]  W. McGuire.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[18]  J. Smith,et al.  Second trial drugs in ovarian cancer. , 1977, Gynecologic oncology.

[19]  A. Hamburger,et al.  Primary bioassay of human tumor stem cells. , 1977, Science.

[20]  K. Kohn,et al.  Effect of pH on the bleomycin-induced DNA single-strand scission in L1210 cells and the relation to cell survival. , 1976, Cancer research.

[21]  C. Griffiths,et al.  Management of ovarian carcinoma. Current concepts and future prospects. , 1976 .

[22]  Young Rc.  Chemotherapy of ovarian cancer: past and present. , 1975, Seminars in oncology.

[23]  F. Zunino,et al.  Daunomycin (Daunorubicin) and Adriamycin and Structural Analogues: Biological Activity and Mechanism of Action , 1975 .

[24]  R. Young.  Chemotherapy of ovarian cancer: past and present. , 1975, Seminars in oncology.

[25]  V. Devita,et al.  Treatment of ovarian carcinoma: possibilities for progress. , 1972, The New England journal of medicine.